Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman’s uterus for a range of genetic problems that can cause implantation failure, miscarriage and birth defects in a resulting child. Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:
- Preimplantation
genetic screening for abnormal chromosome number (PGT-A)
- Preimplantation
genetic testing for monogenic (individual) disease (PGT-M)
- Preimplantation
genetic testing structural rearrangement (PGT-SR) for known chromosomal
misarrangements such as inversion and translocation.
The report Preimplantation Genetic Testing
Market
is projected to reach USD 1.2 billion by 2028 from USD 0.7 billion in 2023, at
a CAGR of 11.4% during the forecast period.
The growth of Preimplantation genetic testing market
is majorly driven by the high risk of chromosomal abnormalities with advancing
maternal age, and the rising number of fertility clinics. Furthermore, the use
of fertility treatment options by single parents and same-sex couples is
expected to drive the growth of the preimplantation genetic testing market.
Download PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605
Key Growth Drivers:
1 Decline in fertility rates
2 Rise of fertility tourism in emerging economies
3 Increasing number of fertility clinics and IVF centers
4 Increasing public-private investments to develop novel diagnostic
techniques.
5 High risk of chromosomal abnormalities with advancing
maternal age
Market Segmentation: -
Preimplantation genetic screening, or aneuploidy
screening, involves screening embryos for the assessment of aneuploidy. This
segment is expected to dominate the global preimplantation genetic testing
market during the forecast period, driven by a decrease in female fertility
with rising maternal age, better implantation rate and reduced IVF cycle times.
By end user, the global preimplantation genetic
testing market is broadly segmented into hospitals, diagnostic labs, fertility
clinics, and other end users. The large share of this segment can be attributed
to factors such as the increasing number of fertility centers globally, the
high success rate of treatment in fertility centers, and growing medical
tourism in developing countries.
Regional Analysis: -
Based on the region, the preimplantation genetic
testing market is segmented into North America, Europe, Asia Pacific, and the
Rest of the World. The North American market is driven by high incidence of
chromosomal disorders, and an increasing number of awareness programs. Europe
is the second-largest market for the preimplantation genetic testing market due
to the low fertility rates and increasing maternal age in the region. Asia
Pacific will observe high growth during the forecast period with its growing
medical tourism for infertility treatment in the region’s countries.
Recent
Developments of Preimplantation Genetic Testing Industry
- In 2023, Thermo Fisher Scientific
Inc. (US) launched two new NGS-based test kits to support preimplantation
genetic testing-aneuploidy (PGT-A), commonly used in vitro fertilization
(IVF) and intracytoplasmic sperm injection (ICSI) research.
- In 2022, The Cooper Companies,
Inc. (US) released the addition of Parental QC, Genetic PN check, and
Origin of Aneuploidy to PGT-A testing as PGT-Complete.
- In 2021, Vitrolife (Sweden)
acquired Igenomix (Spain), a leader in reproductive genetic testing
services primarily for IVF clinics.
Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=605
Top key Players: -
Major players in the preimplantation genetic testing
market include Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Agilent
Technologies, Inc. (US), Revvity (US), and The Cooper Companies, Inc. (US).
No comments:
Post a Comment